DEF 14A: Kodiak Sciences Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Kodiak Sciences will hold its 2024 Annual Meeting of Stockholders virtually on June 4, 2024, to vote on director elections, executive compensation, and the ratification of its independent accounting firm.

Summary

• Kodiak Sciences Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 4, 2024.
• Stockholders of record as of April 5, 2024, are entitled to vote.
• The agenda includes the election of two directors, an advisory vote on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2024.
• To attend the virtual meeting, stockholders must register in advance at www.proxydocs.com/KOD by May 31, 2024.
• The company's lead investigational medicine is tarcocimab tedromer, which is under development for diabetic retinopathy and wet age-related macular degeneration.
• KSI-501 is a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability.
• KSI-101 is a novel anti-IL-6, VEGF-trap bispecific protein, the unconjugated protein portion of KSI-501.
• In 2023, Kodiak announced results from five Phase 3 studies of tarcocimab.
• Three Phase 3 studies of tarcocimab met their primary endpoints across three different diseases (BEACON in RVO, DAYLIGHT in wet AMD, GLOW1 in DR).
• The company plans to finish the clinical development of tarcocimab to enable marketing authorization application and has activated GLOW2, a Phase 3 study in diabetic retinopathy.
• The company also plans to study tarcocimab as a second investigational arm in the Phase 3 DAYBREAK study to evaluate its durability in wet AMD.
• Ursus, Kodiak's commercial scale manufacturing facility, was commissioned as a cGMP facility in January 2023.
• The Phase 1 study of KSI-501 met its objectives of demonstrating that repeated monthly dosing of KSI-501 was safe and well tolerated and achieved clinically meaningful and sustained visual acuity gains in patients.
• Kodiak intends to initiate a dose-finding Phase 1b study of KSI-101 in the second quarter of 2024 and dual Phase 3 studies later in 2024.
• The company ended 2023 with $285.5 million of cash and cash equivalents, which it believes is sufficient to fund operations into 2026.
• The board of directors beneficially owns 44% of the company's common shares outstanding and subject to options and other rights to acquire shares exercisable on or before the 60th day after April 1, 2024.
• Excluding such exercisable options and rights, the board of directors beneficially owns 38% of the company's common shares outstanding as of April 1, 2024.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting clinical trial successes and future plans. However, it also acknowledges setbacks in some clinical trials and the inherent risks in drug development.

Positives

• Three Phase 3 studies of tarcocimab met their primary endpoints across three different diseases (BEACON in RVO, DAYLIGHT in wet AMD, GLOW1 in DR).
• Ursus, Kodiak's commercial scale manufacturing facility, was commissioned as a cGMP facility in January 2023.
• The Phase 1 study of KSI-501 met its objectives of demonstrating that repeated monthly dosing of KSI-501 was safe and well tolerated and achieved clinically meaningful and sustained visual acuity gains in patients.
• The company ended 2023 with $285.5 million of cash and cash equivalents, which it believes is sufficient to fund operations into 2026.

Negatives

• The Phase 3 GLEAM and GLIMMER studies of tarcocimab in patients with diabetic macular edema (DME) did not meet their primary endpoints of showing non-inferior visual acuity gains for tarcocimab dosed every 8 to 24 weeks after 3 monthly loading doses compared to aflibercept given every 8 weeks after 5 monthly loading dose.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially.
• Risks include the durability of prior study results, continued progression of the ABC Platform, timing of Phase 3 studies, achievement of goals, potential use of study results to form the basis of an initial Biologics License Application (BLA), liquidity and financial position, prospects of candidates in the pipeline, ability to execute on the manufacturing development plan, ability to advance the pipeline of drug candidates, and ability to build a leading retinal franchise globally.

Future Outlook

Kodiak plans to finish the clinical development of tarcocimab, initiate a Phase 1b study of KSI-101 in Q2 2024, and initiate dual Phase 3 studies of KSI-101 later in 2024.

Management Comments

• Victor Perlroth, M.D., Chief Executive Officer and Chairman of the Board: 'Together with a talented core team, Dr. Perlroth has built Kodiak on a foundation of scientific and operational excellence with a simple mission to design and develop important new medicines for highly prevalent diseases.'
• Victor Perlroth, M.D., Chief Executive Officer and Chairman of the Board: 'Under Dr. Perlroths leadership, Kodiak is building a pipeline of potentially life transforming ophthalmology drug candidates with the goal to build a leading retinal franchise for the benefit of patients globally.'

Industry Context

Kodiak Sciences is operating in the competitive biopharmaceutical industry, specifically focusing on retinal diseases. The company is developing novel therapies to address unmet needs in the treatment of blindness, competing with established anti-VEGF therapies and exploring new market segments such as retinal inflammatory conditions.

Comparison to Industry Standards

• The document mentions competitors such as Regeneron (aflibercept) in the context of clinical trials.
• The document mentions peer companies for compensation benchmarking including AbCellera Biologics, IVERIC bio, Allakos, Mersana Therapeutics, Allogene Therapeutics, Nektar Therapeutics, Annexon, Ocular Therapeutix, Apellis Pharmaceuticals, Prelude Therapeutics, Denali Therapeutics, REGENXBio, Fate Therapeutics, TG Therapeutics, FibroGen, Viridian Therapeutics, and Iovance Biotherapeutics.

Related Party Transactions

• The company has entered into separate indemnification agreements with each of its directors and certain of its officers.
• The company has granted stock options and RSUs to its named executive officers, other executive officers and its non-employee directors.

Stakeholder Impact

• The company is committed to preventing and treating the leading causes of blindness, which benefits patients.
• The company prioritizes employee value and growth, which benefits employees.
• The company aims to enhance stockholder value through the achievement of corporate objectives, which benefits shareholders.
• The company supports the community at large through charitable initiatives.

Next Steps

• Complete Phase 3 clinical studies for tarcocimab tedromer.
• Advance KSI-501 into a Phase 3 study DAYBREAK in 2024.
• Initiate a dose-finding Phase 1b study of KSI-101 in the second quarter of 2024.
• Initiate dual Phase 3 studies of KSI-101 later in 2024.
• Obtain regulatory feedback on study designs.

Key Dates

Keywords

Kodiak Sciences, Annual Meeting, Tarcocimab, KSI-501, KSI-101, Retinal Diseases, Biopharmaceutical, ABC Platform, Director Election, Executive Compensation, PricewaterhouseCoopers, Proxy Statement